Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Matt Stevenson,1* Rachel Archer,1 Jon Tosh,1 Emma Simpson,1 Emma Everson-Hock,1 John Stevens,1 Monica Hernandez-Alava,1 Suzy Paisley,1 Kath Dickinson,1 David Scott,2 Adam Young3 and Allan Wailoo1

1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
3Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK

*Corresponding author

Corrigendum issued November 2016
Corrigendum DOI: 10.3310/hta20350-c201611
Original DOI: 10.3310/hta20350
This report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
Corrigendum notice

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young and Allan Wailoo

This paper1 is corrected as follows:

Table 209: Information in this table has been updated.

TABLE 209 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population

<table>
<thead>
<tr>
<th>First intervention in the strategy</th>
<th>Discounted costs</th>
<th>Discounted QALYs</th>
<th>CPQ compared with MTX strategy (£)</th>
<th>Incremental CPQ (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TCZ + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>51,559</td>
<td>Extendedly dominated</td>
</tr>
<tr>
<td>ABT i.v. + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>47,533</td>
<td>47,533</td>
</tr>
<tr>
<td>IFX + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>48,424</td>
<td>Dominated</td>
</tr>
<tr>
<td>ADA + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>51,472</td>
<td>Dominated</td>
</tr>
<tr>
<td>CTZ + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>50,467</td>
<td>Extendedly dominated</td>
</tr>
<tr>
<td>GOL + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>51,111</td>
<td>Extendedly dominated</td>
</tr>
<tr>
<td>ETN + MTX</td>
<td>CiC information has been removed</td>
<td>CiC information has been removed</td>
<td>51,436</td>
<td>95,714</td>
</tr>
</tbody>
</table>

CPQ, cost per QALY gained.

CPQ, cost per QALY gained.

DOI: 10.3310/hta20350-c201611

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Reference